Flavonoids as modulators of metabolic reprogramming in renal cell carcinoma (Review)

Oncol Rep. 2024 Dec;52(6):167. doi: 10.3892/or.2024.8826. Epub 2024 Oct 18.

Abstract

Renal cell carcinoma (RCC) is distinguished by its varied metabolic reprogramming driven by tumor suppressor gene dysregulation and oncogene activation. Tumors can adapt nutrient uptake and metabolism pathways to meet the altered biosynthetic, bioenergetic and redox demands of cancer cells, whereas conventional chemotherapeutics and molecular inhibitors predominantly target individual metabolic pathways without addressing this adaptability. Flavonoids, which are well‑known for their antioxidant and anti‑inflammatory properties, offer a unique approach by influencing multiple metabolic targets. The present comprehensive review reveals the intricate processes of RCC metabolic reprogramming, encompassing glycolysis, mitochondrial oxidative phosphorylation and fatty acid biosynthesis. The insights derived from the present review may contribute to the understanding of the specific anticancer mechanisms of flavonoids, potentially paving the way for the development of natural antitumor drugs focused on the metabolic reprogramming of RCC.

Keywords: RCC; Warburg effect; anticancer drug; flavonoids; metabolic reprogramming.

Publication types

  • Review

MeSH terms

  • Carcinoma, Renal Cell* / drug therapy
  • Carcinoma, Renal Cell* / metabolism
  • Carcinoma, Renal Cell* / pathology
  • Fatty Acids / metabolism
  • Flavonoids* / pharmacology
  • Flavonoids* / therapeutic use
  • Glycolysis / drug effects
  • Humans
  • Kidney Neoplasms* / drug therapy
  • Kidney Neoplasms* / metabolism
  • Kidney Neoplasms* / pathology
  • Metabolic Reprogramming
  • Mitochondria / drug effects
  • Mitochondria / metabolism
  • Oxidative Phosphorylation / drug effects

Substances

  • Flavonoids
  • Fatty Acids

Grants and funding

The present study was supported by the National Natural Science Foundation of China (grant nos. 82460510, 82203565, 82103388, and 31960145), Yunnan Province Applied Research Funds (grant nos. 202201AY070001-011, 202201AY070001-043 and 202201AS070077), and Science and Technology Innovation Team of Tumor Metabolism Research, Kunming Medical University (grant no. CXTD202102).